Expanding Access to Bladder Cancer Detection Tools

Enhanced visualization technologies continue to play an important role in improving the detection of carcinoma in situ (CIS) in non–muscle invasive bladder cancer (NMIBC). In this video, Ravi D. Chauhan, MD, FACS, and R. Jonathan Henderson, MD, discuss the diagnostic advantages of advanced cystoscopic imaging modalities as well as the logistical and financial challenges that may limit their use in routine practice.

Both speakers emphasize the importance of ongoing communication between urologists and pathologists to improve awareness of CIS and encourage more comprehensive diagnostic evaluation. Henderson discusses the potential value of blue light cystoscopy, describing it as a highly effective diagnostic tool for identifying CIS. However, he notes that adoption may be constrained by workflow complexity, staffing demands, reimbursement limitations, and the operational burden associated with administering the technology in busy clinical settings.

Chauhan describes similar challenges in ambulatory surgery center environments, where procedural efficiency and case volume often influence treatment decisions. Although narrow-band imaging may offer some diagnostic benefit, he explains that practical considerations such as procedure duration, facility resources, and overall patient throughput may limit broader implementation of blue light cystoscopy. Both speakers express optimism that future reimbursement and workflow improvements could help expand access to advanced detection technologies for patients with NMIBC.

Editor’s Note: Ravi D. Chauhan, MD, FACS, reports relevant disclosures with Ferring Pharmaceuticals, UroGen Pharma, AstraZeneca, and Merck. R. Jonathan Henderson, MD, reports relevant disclosures with Janssen, UroGen Pharma, AstraZeneca, and Pfizer.